Professor Hirohide Saito (Department of Life Science Frontiers at CiRA / The University of Tokyo) and Assistant Professor ...

Drs Olga Brieieva and Martin Higgs discuss in vitro genomic models for predicting clinical resistance to PARP inhibitors for ...

Influenza A virus utilizes RNA throughout infection. Little is known, however, about the roles of RNA structures. A previous bioinformatics survey predicted multiple regions of influenza A virus that ...

mRNA vaccines teach the immune system to target specific proteins, often proteins found on a pathogen, like a virus. To do this, they use instructions carried in a genetic molecule called ...

This pre-mRNA is then processed—spliced, possibly edited, capped, and polyadenylated—to increase its stability and expand the diversity of proteins it can code for.

Aided by two molecular control factors, the spliceosome rejects pre-mRNA that could be incorrectly spliced. While GPATCH1 detects the defective pre-mRNA, DHX35 removes it from the spliceosome, which ...

Imagine you're a scientist, tasked with the challenge of rapidly producing large quantities of high-quality messenger RNA (mRNA) for use in cutting-edge medical treatments. Where do you even start?

Pre-eclampsia is usually diagnosed on the basis of high blood pressure after the 20th week of pregnancy, along with signs of kidney damage, such as proteins in urine.

Nuclear pre-mRNA half-life showed the narrowest distribution, ranging from 10 to 46 min (10th and 90th percentile, resp.) with a median of 22 min. Cytosolic transcript half-lives displayed the widest ...

“STX-001 represents the first programmable mRNA therapy in oncology to enter the clinic for the treatment of solid tumors,” said Jake Becraft, Ph.D., CEO & Co-Founder, Strand Therapeutics.

BOSTON, May 30, 2024--Strand Therapeutics, the world’s first programmable mRNA company developing curative therapies for cancer, autoimmune diseases, and beyond, today announced the first ...